MORPHOTEK AND BAXTER EXTEND AGREEMENT

Morphotek announced that it has broadened its manufacturing supply agreement with Baxter Healthcare Corporation to support the development and manufacture of its therapeutic antibody pipeline. The extended agreement will reserve capacity for manufacturing of Morphotek's lead compound MORAb-003, which is in Phase I clinical trials for ovarian cancer at Memorial Sloan Kettering. This is in addition to current manufacturing for MORAb-009, which is being developed for pancreatic cancer and MORAb-004, which targets a proprietary antigen whose expression is restricted to the cell surface of embryonic endothelia cells of vessels associated with neovascular disease.

Yahoo News (http://biz.yahoo.com/prnews/050630/phth020.html?.v=17)